Engineered antibodies to combat viral threats

Xiaojie Yu () and Mark S. Cragg ()

Nature, 2020, vol. 588, issue 7838, 398-399

Abstract: As the COVID-19 pandemic rages globally, interest in antiviral treatments has never been higher. Antibodies are key defence components, and engineering them to better exploit their natural functions might boost therapeutic options.

Keywords: Immunology; SARS-CoV-2; Virology (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-020-03196-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:588:y:2020:i:7838:d:10.1038_d41586-020-03196-2

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-020-03196-2

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().